Market Intelligence, Clinical Progress, and High-Purity Reagents for Retinopathy and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FZD4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FZD4 CRD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View FZD4 Products |
| Gene Delivery | FZD4 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation (Flow Cytometry/Reporter Assay). |
View FZD4 Products |
| Benchmark Ab | Anti-FZD4 Recombinant Antibody (SZN-413/Clinical Benchmarks) Recombinant positive control for binding and functional assays. |
View FZD4 Products |
| Validator | FZD4 siRNA Set Target-specific knockdown verification in functional assays. |
View FZD4 Products |
| Related Target A | LRP5 Essential co-receptor in the Norrin/Wnt-beta-catenin signaling pathway. |
View LRP5 Products |
| Related Target B | NDP (Norrin) High-affinity ligand for FZD4, critical for vascular development assays. |
View NDP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational preservation of 7-TM GPCR-like structure | Lentivirus-driven stable cell line generation for native cell-based functional assays. |
| Selectivity screening against Frizzled family (FZD1-10) | Sequence-verified FZD family CRD-Fc recombinant proteins for cross-reactivity profiling. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for target-specific knockdown verification. |
Live FZD4/CD344 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FZD4 therapeutics is intensifying, with major players shifting focus from broad Wnt-pathway inhibitors to tissue-specific agonists. FZD4 (Frizzled-4), as a key receptor in the Norrin-beta-catenin pathway, is central to blood-retinal barrier maintenance and vascular regeneration. While early oncology pipelines targeted FZD4 with antagonistic antibodies to inhibit cancer stemness, the next wave of R&D is heavily focused on FZD4-selective agonistic bispecific antibodies (e.g., targeting FZD4 and LRP5 simultaneously) for treating retinal vascular diseases such as wet AMD, diabetic retinopathy, and Familial Exudative Vitreoretinopathy (FEVR).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific Antibody (Agonist) | Surrozen (SZN-413) | Retinal Vascular Diseases, FEVR, AMD | Dual-targeting validation (Requires high-purity FZD4 CRD and LRP5 ECD-Fc proteins) |
| Monoclonal Antibody (Antagonist) | OncoMed / Preclinical Pipelines | Glioblastoma, Stem-like Cancers | Inhibition validation (Requires FZD4-stable cell lines generated via Lentivirus) |
| Recombinant Protein (Decoy) | Academic Institutes | Vascular Disorders, Oncology | Binding kinetic analysis (Requires sequence-verified FZD4 CRD-Fc and NDP ligands) |